bioAffinity Technologies, Inc. — Director's Dealing 2023

Jul 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2023-01-01

Reporting Person: Zannes Maria (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-01	Common Stock	A	8227	$2.28	Acquired	69895	Direct
2023-04-15	Common Stock	A	9920	$1.89	Acquired	79815	Direct
2023-06-06	Common Stock	A	26178	$1.91	Acquired	105993	Direct
2023-07-01	Common Stock	A	10245	$1.83	Acquired	116238	Direct

Footnotes

F1: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Ms. Zannes of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

F2: Represents a grant from the Issuer to Ms. Zannes of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Ms. Zannes continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

F3: Represents a grant of 26,178 shares of Common Stock to Ms. Zannes on June 6, 2023 pursuant to Unanimous Written Consent of the Board of Directors of the Issuer dated November 17, 2022.

F4: Represents a grant from the Issuer to Ms. Zannes of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.